Dyadic International (DYAI) Assets Average (2019 - 2026)
Dyadic International (DYAI) posted Assets Average of $8.9 million for Q1 2026, down 17.87% sequentially from $10.8 million in Q4 2025, and little changed YoY from $8.9 million in Q1 2025.
Dyadic International (DYAI) Assets Average (2019 - 2026) Analysis & Trends
Dyadic International has reported Assets Average for 8 years, with the latest figure at $8.9 million in Q1 2026.
- Quarterly Assets Average changed 0.39% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (changed 0.39% YoY) and the FY2025 annual result came in at $9.9 million, up 9.51% from the prior year.
- Assets Average fell to $8.9 million in Q1 2026 per DYAI's latest filing, from $10.8 million in the prior quarter.
- Over five years, Assets Average peaked at $9.3 billion in Q1 2022 and troughed at $8.0 million in Q2 2025.
- A 5-year average of $1.1 billion and a median of $10.7 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average surged 33789.36% in 2022, then tumbled 99.87% in 2023.
- Over 5 years, Assets Average stood at $14.5 million in 2022, then plunged by 39.6% to $8.7 million in 2023, then climbed by 18.66% to $10.4 million in 2024, then grew by 4.26% to $10.8 million in 2025, then declined by 17.87% to $8.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $8.9 million, $10.8 million, and $9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | 8.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.88 Mn |
| Dec 31, 2025 | 10.81 Mn |
| Sep 30, 2025 | 9.91 Mn |
| Jun 30, 2025 | 8.02 Mn |
| Mar 31, 2025 | 8.91 Mn |
| Dec 31, 2024 | 10.37 Mn |
| Sep 30, 2024 | 10.72 Mn |
| Jun 30, 2024 | 11.66 Mn |
| Mar 31, 2024 | 10.45 Mn |
| Dec 31, 2023 | 8.74 Mn |
| Sep 30, 2023 | 10.17 Mn |
| Jun 30, 2023 | 11.94 Mn |
| Mar 31, 2023 | 13.26 Mn |
| Dec 31, 2022 | 14.47 Mn |
| Sep 30, 2022 | 16.22 Mn |
| Jun 30, 2022 | 9.27 Bn |
| Mar 31, 2022 | 9.28 Bn |
| Dec 31, 2021 | 22.58 Mn |
| Sep 30, 2021 | 25.16 Mn |
| Jun 30, 2021 | 27.36 Mn |